⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1086891 | 0.83 | — | — | |
| SCHEMBL162440 | 0.83 | — | — | |
| Ammonia Solution, Strong SCHEMBL27736000 | 0.81 | ALDH1A1 (0.42) | — | |
| SCHEMBL776347 | 0.80 | — | — | |
| SCHEMBL653853 | 0.80 | ALDH1A1 (0.46) | — | |
| SCHEMBL2321956 | 0.80 | — | — | |
| SCHEMBL36821 | 0.80 | — | — | |
| SCHEMBL4427462 | 0.80 | MMP8 (0.47) | — | |
| SCHEMBL776058 | 0.80 | — | — | |
| SCHEMBL7716309 | 0.79 | HDAC4 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| WO-2019245008-A1 | METHOD FOR PRODUCING FLUORINATED COMPOUND | ダイキン工業株式会社 | 2019-12-26 | — | — | WO | disclosed |
| WO-2018141991-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2018-08-09 | — | — | WO | disclosed |
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | HOFFMANN-LA ROCHE INC. | 2015-11-12 | — | — | US | disclosed |
| US-9115098-B2 | 1,3-oxazines as BACE1 and/or BACE2 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-8987255-B2 | Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140243325-A1 | 1,3-Oxazines as Bace1 and/or Bace2 Inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2564850-B1 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-08-13 | — | — | EP | disclosed |
| US-8754075-B2 | 1,3-oxazines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| EP-2205241-B1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-05-21 | — | — | EP | disclosed |
| EP-2697208-A1 | 1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2014-02-19 | — | — | EP | disclosed |
| US-8450520-B2 | Process for preparation of 2-fluoroacrylic esters | CENTRAL GLASS COMPANY, LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| US-8450520-B2 | Process for preparation of 2-fluoroacrylic esters | CENTRAL GLASS COMPANY, LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| US-8450520-B2 | Process for preparation of 2-fluoroacrylic esters | CENTRAL GLASS COMPANY, LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| WO-2012168164-A1 | HALOGEN-ALKYL-1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012139993-A1 | 1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-18 | — | — | WO | disclosed |
| US-20120258962-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2012-10-11 | — | — | US | disclosed |
| EP-2444389-A1 | PROCESS FOR PREPARATION OF 2-FLUOROACRYLIC ESTERS | Central Glass Company, Limited (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120059187-A1 | Process for Preparation of 2-Fluoroacrylic Esters | CENTRAL GLASS COMPANY, LIMITED (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059187-A1 | Process for Preparation of 2-Fluoroacrylic Esters | CENTRAL GLASS COMPANY, LIMITED (JP) | 2012-03-08 | — | — | US | disclosed |